{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,2]],"date-time":"2026-10-02T03:02:11Z","timestamp":1790910131357,"version":"4.1.0"},"reference-count":38,"publisher":"American Society for Microbiology","issue":"4","license":[{"start":{"date-parts":[[2013,4,1]],"date-time":"2013-04-01T00:00:00Z","timestamp":1364774400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/journals.asm.org\/non-commercial-tdm-license"}],"content-domain":{"domain":["journals.asm.org"],"crossmark-restriction":true},"short-container-title":["Clin Vaccine Immunol"],"published-print":{"date-parts":[[2013,4]]},"abstract":"<jats:title>ABSTRACT<\/jats:title>\n          <jats:p>\n            Current serodiagnostic assays for Lyme disease are inadequate at detecting early infection due to poor sensitivity and nonspecificity that arise from the use of whole bacteria or bacterial proteins as assay targets; both targets contain epitopes that are cross-reactive with epitopes found in antigens of other bacterial species. Tests utilizing peptides that contain individual epitopes highly specific for\n            <jats:named-content content-type=\"genus-species\">Borrelia burgdorferi<\/jats:named-content>\n            as diagnostic targets are an attractive alternative to current assays. Using an overlapping peptide library, we mapped linear epitopes in OspC, a critical virulence factor of\n            <jats:named-content content-type=\"genus-species\">B. burgdorferi<\/jats:named-content>\n            required for mammalian infection, and confirmed the results by enzyme-linked immunosorbent assay (ELISA). We identified a highly conserved 20-amino-acid peptide epitope, OspC1. Via ELISA, OspC1 detected specific IgM and\/or IgG in 60 of 98 serum samples (62.1%) obtained from patients with erythema migrans (early Lyme disease) at the time of their initial presentation. By comparison, the commercially available OspC peptide PepC10 detected antibody in only 48 of 98 serum samples (49.0%). In addition, OspC1 generated fewer false-positive results among negative healthy and diseased (rheumatoid arthritis and positive Rapid Plasma Reagin [RPR+] test result) control populations than did PepC10. Both highly specific and more sensitive than currently available OspC peptides, OspC1 could have value as a component of a multipeptide Lyme disease serological assay with significantly improved capabilities for the diagnosis of early infection.\n          <\/jats:p>","DOI":"10.1128\/cvi.00608-12","type":"journal-article","created":{"date-parts":[[2013,1,31]],"date-time":"2013-01-31T03:43:36Z","timestamp":1359603816000},"page":"474-481","update-policy":"https:\/\/doi.org\/10.1128\/asmj-crossmark-policy-page","source":"Crossref","is-referenced-by-count":55,"title":["Outer Surface Protein C Peptide Derived from Borrelia burgdorferi Sensu Stricto as a Target for Serodiagnosis of Early Lyme Disease"],"prefix":"10.1128","volume":"20","author":[{"given":"Paul M.","family":"Arnaboldi","sequence":"first","affiliation":[{"name":"Biopeptides Corp., East Setauket, New York, USA"},{"name":"Department of Microbiology, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Rudra","family":"Seedarnee","sequence":"additional","affiliation":[{"name":"Department of Microbiology, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mariya","family":"Sambir","sequence":"additional","affiliation":[{"name":"Biopeptides Corp., East Setauket, New York, USA"},{"name":"Department of Microbiology, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steven M.","family":"Callister","sequence":"additional","affiliation":[{"name":"Gundersen Lutheran Medical Center, La Crosse, Wisconsin, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josephine A.","family":"Imparato","sequence":"additional","affiliation":[{"name":"Biopeptides Corp., East Setauket, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Raymond J.","family":"Dattwyler","sequence":"additional","affiliation":[{"name":"Biopeptides Corp., East Setauket, New York, USA"},{"name":"Department of Microbiology, New York Medical College, Valhalla, New York, USA"},{"name":"Department of Medicine, New York Medical College, Valhalla, New York, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"235","reference":[{"key":"e_1_3_3_2_2","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1016\/S0140-6736(11)60103-7","article-title":"Lyme borreliosis","volume":"379","author":"Stanek G","year":"2012","unstructured":"StanekG WormserGP GrayJ StrleF. 2012. Lyme borreliosis. Lancet 379:461\u2013473.","journal-title":"Lancet"},{"key":"e_1_3_3_3_2","doi-asserted-by":"publisher","DOI":"10.1056\/NEJM200107123450207"},{"key":"e_1_3_3_4_2","doi-asserted-by":"crossref","first-page":"521","DOI":"10.1086\/649921","article-title":"A commentary on the treatment of early Lyme disease","volume":"50","author":"Dattwyler RJ","year":"2010","unstructured":"DattwylerRJ. 2010. A commentary on the treatment of early Lyme disease. Clin. Infect. Dis. 50:521\u2013522.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_5_2","doi-asserted-by":"crossref","first-page":"261","DOI":"10.1016\/S0025-7125(03)00086-5","article-title":"Neurologic aspects of Lyme disease","volume":"86","author":"Coyle PK","year":"2002","unstructured":"CoylePK SchutzerSE. 2002. Neurologic aspects of Lyme disease. Med. Clin. North Am. 86:261\u2013284.","journal-title":"Med. Clin. North Am."},{"key":"e_1_3_3_6_2","doi-asserted-by":"crossref","first-page":"725","DOI":"10.7326\/0003-4819-107-5-725","article-title":"The clinical evolution of Lyme arthritis","volume":"107","author":"Steere AC","year":"1987","unstructured":"SteereAC SchoenRT TaylorE. 1987. The clinical evolution of Lyme arthritis. Ann. Intern. Med. 107:725\u2013731.","journal-title":"Ann. Intern. Med."},{"key":"e_1_3_3_7_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00330-07"},{"key":"e_1_3_3_8_2","first-page":"4","article-title":"Nervous system Lyme disease: diagnosis and treatment","volume":"6","author":"Halperin JJ","year":"2009","unstructured":"HalperinJJ. 2009. Nervous system Lyme disease: diagnosis and treatment. Rev. Neurol. Dis. 6:4\u201312.","journal-title":"Rev. Neurol. Dis."},{"key":"e_1_3_3_9_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.43.2.850-856.2005"},{"key":"e_1_3_3_10_2","first-page":"590","article-title":"Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease","volume":"44","author":"Centers for Disease Control and Prevention (CDC)","year":"1995","unstructured":"Centers for Disease Control and Prevention (CDC). 1995. Recommendations for test performance and interpretation from the Second National Conference on Serologic Diagnosis of Lyme Disease. MMWR Morb. Mortal. Wkly. Rep. 44:590\u2013591.","journal-title":"MMWR Morb. Mortal. Wkly. Rep."},{"key":"e_1_3_3_11_2","doi-asserted-by":"publisher","DOI":"10.1128\/CMR.18.3.484-509.2005"},{"key":"e_1_3_3_12_2","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.1086\/314651","article-title":"A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease","volume":"179","author":"Porwancher R","year":"1999","unstructured":"PorwancherR. 1999. A reanalysis of IgM Western blot criteria for the diagnosis of early Lyme disease. J. Infect. Dis. 179:1021\u20131024.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_13_2","doi-asserted-by":"crossref","first-page":"1236","DOI":"10.1111\/j.1469-0691.2011.03749.x","article-title":"High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice","volume":"18","author":"Seriburi V","year":"2012","unstructured":"SeriburiV NdukweN ChangZ CoxME WormserGP. 2012. High frequency of false positive IgM immunoblots for Borrelia burgdorferi in clinical practice. Clin. Microbiol. Infect. 18:1236\u20131240.","journal-title":"Clin. Microbiol. Infect."},{"key":"e_1_3_3_14_2","doi-asserted-by":"crossref","first-page":"2015","DOI":"10.1001\/archinte.161.16.2015","article-title":"A first-tier rapid assay for the serodiagnosis of Borrelia burgdorferi infection","volume":"161","author":"Gomes-Solecki MJ","year":"2001","unstructured":"Gomes-SoleckiMJ WormserGP PersingDH BergerBW GlassJD YangX DattwylerRJ. 2001. A first-tier rapid assay for the serodiagnosis of Borrelia burgdorferi infection. Arch. Intern. Med. 161:2015\u20132020.","journal-title":"Arch. Intern. Med."},{"key":"e_1_3_3_15_2","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1093\/genetics\/151.1.15","article-title":"Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto","volume":"151","author":"Wang I","year":"1999","unstructured":"WangI DykhuizenDE QiuW DunnJJ BoslerEM LuftBJ. 1999. Genetic diversity of ospC in a local population of Borrelia burgdorferi sensu stricto. Genetics 151:15\u201330.","journal-title":"Genetics"},{"key":"e_1_3_3_16_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.41.6.2791.2003"},{"key":"e_1_3_3_17_2","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1086\/648674","article-title":"2-Tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test","volume":"50","author":"Branda JA","year":"2010","unstructured":"BrandaJA Aguero-RosenfeldME FerraroMJ JohnsonBJB WormserGP SteereAC. 2010. 2-Tiered antibody testing for early and late Lyme disease using only an immunoglobulin G blot with the addition of a VlsE band as the second-tier test. Clin. Infect. Dis. 50:20\u201326.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_18_2","doi-asserted-by":"crossref","first-page":"541","DOI":"10.1093\/cid\/cir464","article-title":"Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay","volume":"53","author":"Branda JA","year":"2011","unstructured":"BrandaJA LinskeyK KimYA SteereAC FerraroMJ. 2011. Two-tiered antibody testing for Lyme disease with use of 2 enzyme immunoassays, a whole-cell sonicate enzyme immunoassay followed by a VlsE C6 peptide enzyme immunoassay. Clin. Infect. Dis. 53:541\u2013547.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_19_2","doi-asserted-by":"publisher","DOI":"10.1128\/mBio.00153-10"},{"key":"e_1_3_3_20_2","doi-asserted-by":"publisher","DOI":"10.1086\/374395"},{"key":"e_1_3_3_21_2","doi-asserted-by":"crossref","first-page":"346","DOI":"10.1093\/infdis\/174.2.346","article-title":"Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting","volume":"174","author":"Johnson BJB","year":"1996","unstructured":"JohnsonBJB RobbinsKE BaileyRE CaoB SviatSL CravenRB MayerLW DennisDT. 1996. Serodiagnosis of Lyme disease: accuracy of a two-step approach using a flagella-based ELISA and immunoblotting. J. Infect. Dis. 174:346\u2013353.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_22_2","first-page":"1","article-title":"Case definitions for infectious conditions under public health surveillance","volume":"46","author":"Anonymous","year":"1997","unstructured":"Anonymous. 1997. Case definitions for infectious conditions under public health surveillance. MMWR Recommend. Rep. 46:1\u201355.","journal-title":"MMWR Recommend. Rep."},{"key":"e_1_3_3_23_2","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1086\/324490","article-title":"Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques","volume":"33","author":"Nowakowski J","year":"2001","unstructured":"NowakowskiJ SchwartzI LiverisD WangG Aguero-RosenfeldME GiraoG McKennaD NadelmanRB CavaliereLF WormserGP Lyme Disease StudyGroup. 2001. Laboratory diagnostic techniques for patients with early Lyme disease associated with erythema migrans: a comparison of different techniques. Clin. Infect. Dis. 33:2023\u20132027.","journal-title":"Clin. Infect. Dis."},{"key":"e_1_3_3_24_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.37.12.3990-3996.1999"},{"key":"e_1_3_3_25_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00122-07"},{"key":"e_1_3_3_26_2","doi-asserted-by":"publisher","DOI":"10.1128\/JB.185.15.4432-4441.2003"},{"key":"e_1_3_3_27_2","doi-asserted-by":"crossref","first-page":"249","DOI":"10.1016\/j.ijmm.2007.10.002","article-title":"Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): expression patterns during the mammal-tick infection cycle","volume":"298","author":"Bykowski T","year":"2008","unstructured":"BykowskiT WoodmanME CooleyAE BrissetteCA WallichR BradeV KraiczyP StevensonB. 2008. Borrelia burgdorferi complement regulator-acquiring surface proteins (BbCRASPs): expression patterns during the mammal-tick infection cycle. Int. J. Med. Microbiol. 298(Suppl 1):249\u2013256.","journal-title":"Int. J. Med. Microbiol."},{"key":"e_1_3_3_28_2","doi-asserted-by":"crossref","first-page":"9","DOI":"10.1016\/j.diagmicrobio.2012.09.003","article-title":"Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease","volume":"75","author":"Wormser GP","year":"2013","unstructured":"WormserGP SchrieferM Aguero-RosenfeldME LevinA SteereAC NadelmanRB NowakowskiJ MarquesA JohnsonBJB DumlerJS. 2013. Single-tier testing with the C6 peptide ELISA kit compared with two-tier testing for Lyme disease. Diagn. Microbiol. Infect. Dis. 75:9\u201315.","journal-title":"Diagn. Microbiol. Infect. Dis."},{"key":"e_1_3_3_29_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.00048-08"},{"key":"e_1_3_3_30_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.01950-05"},{"key":"e_1_3_3_31_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.36.12.3474-3479.1998"},{"key":"e_1_3_3_32_2","doi-asserted-by":"crossref","first-page":"731","DOI":"10.1099\/0022-1317-51-9-731","article-title":"Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii in the serodiagnosis of Lyme borreliosis","volume":"51","author":"Panelius J","year":"2002","unstructured":"PaneliusJ LahdenneP HeikkillaT PeltomaaM OksiJ SeppalaI. 2002. Recombinant OspC from Borrelia burgdorferi sensu stricto, B. afzelii and B. garinii in the serodiagnosis of Lyme borreliosis. J. Med. Microbiol. 51:731\u2013739.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_3_33_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.34.2.237-240.1996"},{"key":"e_1_3_3_34_2","doi-asserted-by":"crossref","first-page":"724","DOI":"10.1093\/infdis\/171.3.724","article-title":"Recombinant outer surface protein C ELISA for the diagnosis of early Lyme disease","volume":"171","author":"Gerber MA","year":"1995","unstructured":"GerberMA ShapiroED BellGL SampieriA PadulaSJ. 1995. Recombinant outer surface protein C ELISA for the diagnosis of early Lyme disease. J. Infect. Dis. 171:724\u2013727.","journal-title":"J. Infect. Dis."},{"key":"e_1_3_3_35_2","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1099\/00222615-48-1-5","article-title":"Advantage of recombinant borrelial proteins for serodiagnosis of neuroborreliosis","volume":"48","author":"Kaiser R","year":"1999","unstructured":"KaiserR RauerS. 1999. Advantage of recombinant borrelial proteins for serodiagnosis of neuroborreliosis. J. Med. Microbiol. 48:5\u201310.","journal-title":"J. Med. Microbiol."},{"key":"e_1_3_3_36_2","doi-asserted-by":"publisher","DOI":"10.1128\/CVI.00409-06"},{"key":"e_1_3_3_37_2","doi-asserted-by":"publisher","DOI":"10.1128\/jcm.33.7.1860-1866.1995"},{"key":"e_1_3_3_38_2","doi-asserted-by":"publisher","DOI":"10.1128\/IAI.73.12.7869-7877.2005"},{"key":"e_1_3_3_39_2","doi-asserted-by":"publisher","DOI":"10.1128\/JCM.38.5.1735-1739.2000"}],"container-title":["Clinical and Vaccine Immunology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00608-12","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/journals.asm.org\/doi\/pdf\/10.1128\/CVI.00608-12","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,7,29]],"date-time":"2021-07-29T20:48:56Z","timestamp":1627591736000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.asm.org\/doi\/10.1128\/CVI.00608-12"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,4]]},"references-count":38,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2013,4]]}},"alternative-id":["10.1128\/CVI.00608-12"],"URL":"https:\/\/doi.org\/10.1128\/cvi.00608-12","relation":{},"ISSN":["1556-6811","1556-679X"],"issn-type":[{"value":"1556-6811","type":"print"},{"value":"1556-679X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2013,4]]},"assertion":[{"value":"2012-10-18","order":0,"name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-01-02","order":1,"name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}},{"value":"2013-03-25","order":2,"name":"published","label":"Published","group":{"name":"publication_history","label":"Publication History"}}]}}